Login
$QURE
$21.83 -$0.05 (0.23%) After hours

$QURE 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~

02 Nov 2026 8-K: Regulation FD Disclosure; Other Events

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

29 Sep 2026 8-K: Regulation FD Disclosure

Ashley – Huntington’s Disease Community Advocate Phase I/II ifezuntirgene inilparvovec (AMT-130) Huntington’s Disease Program Update September 29, 2026

02 Sep 2026 8-K: Regulation FD Disclosure

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

29 Jul 2026 8-K: Results of Operations and Financial Condition

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

24 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

As representative (the “Representative”) of the several Underwriters

22 Jun 2026 8-K: Regulation FD Disclosure; Other Events

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

17 Jun 2026 8-K: Other Events

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~

15 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

This is a translation into English of the official Dutch version of the articles of association of a public company with limited liability under Dutch law. Definitions included in article 1 below appear in the English alphabetical order ...

05 May 2026 8-K: Results of Operations and Financial Condition

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~

30 Apr 2026 8-K: Regulation FD Disclosure

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected

02 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~

13 Jan 2026 8-K: Regulation FD Disclosure

Sophia – Huntington’s Disease Community Advocate Leadership in Gene Therapy January 2026 Exhibit 99.1

09 Jan 2026 8-K: Regulation FD Disclosure

Lexington, MA and Amsterdam, the Netherlands, January 9, 2026 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with ...

04 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Lexington, MA and Amsterdam, the Netherlands, December 4, 2025 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company rece...

10 Nov 2025 8-K: Results of Operations and Financial Condition

~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary andkey secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 monthsand supportive trend...

03 Nov 2025 8-K: Regulation FD Disclosure; Other Events

Lexington, MA and Amsterdam, the Netherlands, November 3, 2025 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feed...

29 Sep 2025 8-K: Entry into a Material Definitive Agreement; Other Events

As representative (the “Representative”) of the several Underwriters

24 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

[***] CERTAIN INFORMATION HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10)(IV) FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

24 Sep 2025 8-K: Regulation FD Disclosure; Other Events

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support